<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the last decade the concepts of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> <z:e sem="disease" ids="C0002793" disease_type="Neoplastic Process" abbrv="">dedifferentiation</z:e> and progression have undergone a significant and substantial change </plain></SENT>
<SENT sid="1" pm="."><plain>In the past it was widely believed that the detailed associations between genetic and morphological changes defined in the Vogelstein model of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> pathogenesis could be transferred to breast <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A multitude of studies seemed to verify this a priori hypothesis </plain></SENT>
<SENT sid="3" pm="."><plain>However, with the introduction of global screening techniques, predominantly at the DNA level, it became obvious that this linear model might be oversimplified for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>It is now widely accepted that losses of chromosomal 16q characterize in-situ and invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with predominantly low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> grade and <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor (ER) positivity (<z:chebi fb="2" ids="8069">luminal</z:chebi> <z:hpo ids='HP_0003002'>breast cancers</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, high grade <z:hpo ids='HP_0003002'>breast cancers</z:hpo> of the HER2, the basal or the non expressor phenotype with 16q-losses are rarely seen and in consequence a concept of multiple, parallel pathways with defined precursor lesions emerged </plain></SENT>
<SENT sid="6" pm="."><plain>As a consequence, it became obvious that the hunt for oncogenes/<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes in invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> is pathway specific </plain></SENT>
<SENT sid="7" pm="."><plain>Whereas high grade <z:hpo ids='HP_0003002'>breast cancers</z:hpo> have been relatively well characterized by several recurrent changes in oncogenes/<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes located on various chromosomal regions (e.g. egfr, p53, HER2), the characterization of a 16q-specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene in ER-positive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> is still a tremendous challenge </plain></SENT>
<SENT sid="8" pm="."><plain>This review will focus on the role of 16q in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and aims to give insights into actual research efforts, e.g. alternative explanations in order to unravel the central role of 16q in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>